Opin vísindi

Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland

Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland


Title: Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland
Author: Sigurdsson, Samuel   orcid.org/0000-0001-7517-6973
Eyþórsson, Elías
Erlendsdóttir, Helga
Hrafnkelsson, Birgir   orcid.org/0000-0003-1864-9652
Kristinsson, Karl G.
Haraldsson, Ásgeir   orcid.org/0000-0001-5364-7877
Date: 2020-03-10
Language: English
Scope: 2707-2714
University/Institute: Háskóli Íslands
University of Iceland
School: Heilbrigðisvísindasvið (HÍ)
School of Health Sciences (UI)
Verkfræði- og náttúruvísindasvið (HÍ)
School of Engineering and Natural Sciences (UI)
Department: Læknadeild (HÍ)
Faculty of Medicine (UI)
Raunvísindadeild (HÍ)
Faculty of Physical Sciences (UI)
Series: Vaccine;38(12)
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2020.01.094
Subject: Cohort study; IPD; PCV-10; Pneumococcus; Pneumonia; Sepsis; Lungnabólga; Pneumókokkar; Bólusetningar
URI: https://hdl.handle.net/20.500.11815/2396

Show full item record

Citation:

Sigurdsson, S., et al. (2020). "Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland." Vaccine 38(12): 2707-2714.

Abstract:

Introduction: Pneumococcus is an important respiratory pathogen. The 10-valent pneumococcal vaccine (PHiD-CV) was introduced into the Icelandic vaccination programme in 2011. The aim was to estimate the impact of PHiD-CV on paediatric hospitalisations for respiratory tract infections and invasive disease. Methods: The 2005–2015 birth-cohorts were followed until three years of age and hospitalisations were recorded for invasive pneumococcal disease (IPD), meningitis, sepsis, pneumonia and otitis media. Hospitalisations for upper- and lower respiratory tract infections (URTI, LRTI) were used as comparators. The 2005–2010 birth-cohorts were defined as vaccine non-eligible cohorts (VNEC) and 2011–2015 birth-cohorts as vaccine eligible cohorts (VEC). Incidence rates (IR) were estimated for diagnoses, birth-cohorts and age groups, and incidence rate ratios (IRR) between VNEC and VEC were calculated assuming Poisson variance. Cox regression was used to estimate the hazard ratio (HR) of hospitalisation between VNEC and VEC. Results: 51,264 children were followed for 142,315 person-years, accumulating 1,703 hospitalisations for the respective study diagnoses. Hospitalisations for pneumonia decreased by 20% (HR 0.80, 95%CI:0.67–0.95) despite a 32% increase in admissions for LRTI (HR 1.32, 95%CI:1.14–1.53). Hospital admissions for culture-confirmed IPD decreased by 93% (HR 0.07, 95%CI:0.01–0.50) and no hospitalisations for IPD with vaccine-type pneumococci were observed in the VEC. Hospitalisations for meningitis and sepsis did not change. A decrease in hospital admissions for otitis media was observed, but did not coincide with PHiD-CV introduction. Conclusion: Following the introduction of PHiD-CV in Iceland, hospitalisations for pneumonia and culture confirmed IPD decreased. Admissions for other LRTIs and URTIs increased during this period.

Description:

Publisher's version (útgefin grein)

Rights:

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Files in this item

This item appears in the following Collection(s)